Cancer Research The Future of Cancer Research: Science and Patient Impact AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Joos, S.
Right arrow Articles by Lichter, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joos, S.
Right arrow Articles by Lichter, P.
[Cancer Research 60, 549-552, February 1, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Genomic Imbalances Including Amplification of the Tyrosine Kinase Gene JAK2 in CD30+ Hodgkin Cells1

Stefan Joos2, Manfred Küpper, Sibylle Ohl, Frederike von Bonin, Gunhild Mechtersheimer, Martin Bentz, Peter Marynen, Peter Möller, Michael Pfreundschuh, Lorenz Trümper and Peter Lichter

Deutsches Krebsforschungszentrum, Abteilung Organisation Komplexer Genome (H0700), D-69120 Heidelberg [S. J., M. K., S. O., P. L.]; Universitätskliniken des Saarlandes, Innere Medizin I, D-66421 Homburg/Saar [F. v. B., M. P., L. T.]; Pathologisches Institut, Universität Heidelberg, D-69120 Heidelberg [G. M.]; Abteilung Innere Medizin III, D-89081 Ulm [M. B.]; Human Genome Laboratory, B-3000 Leuven [P. Ma.]; Abteilung für Pathologie des Universitätsklinikums Ulm, D-89081 Ulm [P. Mö.], Germany


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Comparative genomic hybridization was applied for a comprehensive screening of frequently occurring net gains and losses of chromosomal subregions in small populations of CD30+ Hodgkin cells and their morphological variants. In 12 Hodgkin’s lymphomas, recurrent gains were detected on chromosomal arms 2p, 9p, and 12q (in six, four, and five tumors, respectively) and distinct high-level amplifications were identified on chromosomal bands 4p16, 4q23-q24, and 9p23-p24. In Hodgkin cells with 9p23-p24 amplification, fluorescence in situ hybridization revealed an increased copy number of chromosomal sequences spanning the tyrosine kinase gene JAK2. Several of the imbalances described, in particular a gain in chromosomal arm 9p that includes JAK2 amplification, are similar to the genomic changes detected in primary mediastinal B-cell lymphoma.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
In Hodgkin’s disease, four well-defined histotypes of cHL3 have been distinguished according to the recent REAL classification, i.e., cHL-LR, cHL-NS, cHL-MC, and cHL-LD, in addition to the clinically and immunophenotypically distinct subtype of paragranuloma, or NLPHL (1) . All subtypes are characterized by the presence of only a small fraction of malignant cells, referred to hereafter as "Hodgkin cells," which exist in several variants: the mononuclear variant, the L&H cell, and the lacunar cell variant, as well as the multinucleated Reed-Sternberg cell (2) . Because of the small numbers, low mitotic index, and frequently poor chromosome morphology of these cells, chromosome banding analysis is particularly difficult and has not revealed specific chromosomal changes that would immediately indicate the localization of genes involved in the etiology of Hodgkin’s disease (3) . Therefore, we used an alternative approach and collected pools of 30 CD30+ Hodgkin cells from a series of 11 cHLs and a single case of NLPHL. The genomic DNA of the pooled cells was subjected to universal PCR amplification and used as probe for CGH. On the basis of the results obtained, the copy number of a candidate gene, JAK2, was analyzed by FISH and Southern blot analysis in Hodgkin cells and PMBL, in which similar chromosomal imbalances have been found previously (4) .


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Tumor Material.
Lymph node biopsies from seven male and five female patients were used for cytogenetic analysis of Hodgkin cells. The mean age of the patients at the time of diagnosis was 38.3 years. The 11 cHLs comprised 1 nodular variant of cHL-LR, 4 cases of cHL-MC, 5 cases of cHL-NS, 1 case of cHL-LD, and 1 case of a nodular variant of NLPHL. Tumors were classified according to the guidelines of the pathology panel of the German Hodgkin’s study, anticipating the upcoming WHO classification (5) based on routinely stained paraffin sections and immunohistology that included stains for CD3, CD15, CD20, and CD30 as well as epithelial membrane antigen. The tumor staging and immunophenotypes of CD3, CD20, and CD30 are listed in Table 1Citation . From each tumor, fresh, unfixed tissue material was available.


View this table:
[in this window]
[in a new window]
  		Table 1 Selected clinicopathological data of investigated cases of Hodgkin’s disease

 
Isolation of Hodgkin Cells.
For isolation of Hodgkin cells, lymph nodes derived from Hodgkin’s disease were prepared as described previously (6) . Briefly, lymphocytes and Hodgkin cells from viable single-cell suspensions were fixed in 3% w/v paraformaldehyde and applied to glass slides by cytospin centrifugation. For immunostaining of CD30 antigen, Alkaline-phosphatase-anti-alkaline-phosphatase assay 4 was applied (6) , using monoclonal antibody HRS-4. Identification of Hodgkin cells was based on positive staining for CD30 antigen and on morphological criteria. In the single case of NLPHL, which exhibited large CD20+/CD30+ malignant cells, primarily morphological criteria were applied. Thirty Hodgkin cells were isolated and collected with glass capillaries, using a micromanipulation device (Eppendorf, Hamburg, Germany).

DOP-PCR.
Hodgkin cells were first digested with proteinase K (250 µg/ml) in 20 µl of 1x PCR buffer (2 mM MgCl2, 50 mM KCl, 10 mM Tris, pH 8.3, 0.1 mg/ml gelatin) for 1 h at 55°C, with subsequent inactivation of the enzyme at 95°C for 15 min. For universal amplification of the genomic DNA, degenerate oligonucleotide-primed DOP-PCR as described by Telenius et al. (7) was applied. After the PCR reaction, excessive DOP primers were separated from the amplified genomic DNA on the appropriate columns (Qiagen, Hilden, Germany).

CGH.
Preparation of metaphase chromosomes, probe labeling, hybridization, and image acquisition were performed as described previously (4 , 8) . Chromosomal imbalances were detected based on the ratio profile deviating from the balanced value of 1.0. Chromosomal regions were scored as gains or losses when the ratio profile either reached or exceeded the diagnostic thresholds of 1.25 or 0.75, respectively. Overrepresentations were considered high-level amplifications when the CGH ratio exceeded the value of 2.0 or when the fluorescence showed a strong distinct signal detected by visual inspection and the corresponding ratio profile was diagnostic for overrepresentation. Centromeric regions as well as chromosomes 1p32-p36 and 19 were not scored in the results for reasons specified elsewhere (9) . The quality of the CGH experiments was assessed using genomic DNA of male individuals as internal control probes; monosomy of the X chromosome was clearly visible in all experiments performed in this study.

FISH.
Hodgkin cells were detected by staining with monoclonal anti-CD30 (HRS-4), a secondary alkaline phosphatase conjugated antibody (Dako Envision; DAKO Diagnostica, Hamburg, Germany) and fast red substrate. Slides were then treated with 1.5% Triton X-100. After denaturation of chromosomal DNA in 70% formamide at 76°C for 5 min, specimens were dehydrated in a series of ethanol solutions and air dried. As probes, PAC clones PJ2A and PJ2B were used, spanning the entire JAK2 gene as well as ~50 kb of the downstream region on chromosome 9p24 (10) . Probe labeling and in situ hybridization were performed as described previously (4) .

Southern Blot Analysis.
Genomic DNA was isolated from peripheral blood, PMBL-derived cell line MedB-1, and a PMBL tumor harboring a distinct high-level amplification of chromosomal band 9p23-p24 (PMBL 16; Fig. 2Citation ; Ref. 4 ). DNA preparation and Southern blot analysis were performed as described elsewhere (11) , using a 880-bp HindIII fragment probe of JAK2 c-DNA. As an internal control, a 2.1-kb EcoRI cDNA clone of WNT2 (American Type Culture Collection, Rockville, MD) located on chromosome 7q31-q32 was used. The level of amplification was calculated by comparison of the hybridization signal intensities of test and control signals on X-ray films using the software application TINA 2.0 (Raytest, Straubenhardt, Germany).



View larger version (50K):
[in this window]
[in a new window]
  		Fig. 2. Examples of CGH experiments showing the detection of distinct amplified genomic sequences in Hodgkin cells (a–c) and PMBL cells (d). Top, average ratio profiles; bottom, examples of hybridized chromosome homologues. Arrows indicate amplification of subbands 4p16 in HDK 7 (a), 4q23-q24 in HDK 4 (b), 9p23-p24 in HDK 12 (c), and 9p23-p24 in PMBL 16 (d; Ref. 4 ). Centromeric regions shaded in gray are excluded from evaluation for reasons indicated elsewhere (9) . Vertical lines indicate average ratio value of 1 (black vertical line) and diagnostic cutoff values for gains (e.g., 1.25, 1.5; gray vertical lines on right) and losses (e.g., 0.75, 0.5; gray vertical lines on left).

 

   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
CGH Analysis.
Universally amplified genomic DNA of 30 CD30+ Hodgkin cells from 12 different Hodgkin’s lymphomas was analyzed by CGH. The net chromosomal gains and losses of chromosomal regions that where identified are summarized in Fig. 1Citation . Fifty-three imbalances were detected in Hodgkin cell pools in 11 of 12 of the analyzed tumors, with an average number of 4.4 imbalances per case (range, 0–8 imbalances). Gains were detected much more frequently than losses: 48 gains (4.0 per tumor) versus 5 losses (0.4 per tumor). Chromosomal losses included 17p (2 of 12 tumors), 4q32-qter, 13q31-qter, and 18p (1 of 12 tumors). Overrepresentations most frequently involved chromosomal arms 2p in 6 of 12 tumors, 12q in 5 of 12 tumors, and 9p in 4 of 12 tumors. Twenty-two chromosomal arms were involved in low-frequency gains. High-level amplifications of distinct chromosomal subregions were detected in three different tumors on chromosomal bands 4p16, 4q23-q24, and 9p23-p24 (Fig. 2, a–cCitation ). Both amplifications on chromosome 4 affected cHLs (HDK 4 and HDK 7), whereas the one on chromosome 9p was found in the NLPHL subtype (HDK 12).



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 1. Summary of the CGH data of Hodgkin cells isolated from 12 cases of Hodgkin’s disease. Chromosomal gains are indicated by vertical lines to the right, losses by vertical lines to the left of the chromosome ideograms. Distinct high-level amplifications are indicated as bold bars.

 
Detection of JAK2 Copy Number Amplification in NLPHL and PMBL.
The amplified chromosomal region 9p23-p24 constitutes the consensus region that is recurrently gained in neoplastic cells of Hodgkin’s lymphomas in ~33% and PMBL in ~50% of cases (4 , 12) . One candidate gene at this site, JAK2, codes for a non-receptor tyrosine kinase that plays a key role in cytokine signal transduction. To determine whether this gene is involved in the high-level amplification of NLPHL, case 12 (Fig. 2c)Citation , FISH with two PAC clones covering the JAK2 genomic region was applied (Fig. 3)Citation . In 24 CD30+ Hodgkin cells evaluated, an average signal number of 18.5 ± 10.3 was detected. In addition, hybridization signals were frequently clustered in a domain-like signal pattern. Both the high signal number and the spatial signal distribution strongly indicate amplification of the genomic region of JAK2 in these cells. Cells surrounding the CD30+ cells exclusively exhibited two JAK2 signals, i.e., were in disomic state.



View larger version (93K):
[in this window]
[in a new window]
  		Fig. 3. Interphase FISH of Hodgkin cells and adjacent cells in NLPHL case HDK 12. As probes, two PAC clone representative for the JAK2 genomic region on chromosome 9p23-p24 were used. Neoplastic cells were identified by positive staining with anti-CD30 antibody (not shown). A, images of Hodgkin cells and smaller adjacent cells visualized with 4',6-diamidino-2-phenylindole; B, detection of multiple JAK2 signals in large Hodgkin cells, indicating that JAK2 is included in the amplicon on 9p23-p24.

 
Whereas Southern blot analysis is prohibited by the small fraction of Hodgkin cells in primary Hodgkin’s lymphomas, it is a feasible approach for PMBL. The copy number of JAK2 was assessed in genomic DNA of peripheral blood cells, cells from a PMBL-derived cell line (MedB-1), and cells from a primary PMBL tumor (PMBL 16) harboring a high-level amplification of 9p23-p24 (Fig. 2dCitation ; Ref. 4 ). Using a JAK2 cDNA fragment as probe, six hybridization signals were detected in HindIII-digested genomic DNA (3, 3.3, 4.5, 5, 6.6, and 9.3 kb in length). Measurement of the hybridization signals of JAK2 and signals of an internal control probe WNT2 (~4.5, 6, 7.5, and 8 kb in length) revealed an ~19-fold higher intensity in PMBL 16 and a 4-fold higher intensity in MedB-1 compared with normal DNA (Fig. 4)Citation .



View larger version (47K):
[in this window]
[in a new window]
  		Fig. 4. Southern blot analysis of HindIII-digested normal genomic DNA of peripheral blood (Norm.), DNA from PMBL-derived cell line MedB-1, and DNA from PMBL 16, using a JAK2 cDNA probe as well as the internal control probe WNT2. JAK2 is amplified ~4-fold in PMBL cell line BHD-1 and 19-fold in the primary tumor PMBL 16. Only the 6.6-kb signal of JAK2 and the 4.5-kb signal of WNT2 are shown.

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
In the present study, chromosomal imbalances were detected in small populations of Hodgkin cells by a combined approach of universal PCR and CGH. The feasibility of this method has been shown previously, (e.g., Ref. 13 ). The protocol applied here was thoroughly assessed prior to the present study, demonstrating that we could reliably obtain valid CGH data from >=20 pooled cells (data not shown).

Despite of the restricted number of Hodgkin’s lymphomas investigated, a distinct pattern of chromosomal imbalances emerged from this analysis. Gains were detected on chromosomal arms 2p, 9p, and 12q in 33–50% of cases, whereas most other chromosomes were affected in only one or two tumors. CGH also identified amplified DNA sequences from distinct chromosomal subregions, i.e., on 4p16, 4q23-q24, and 9p23-p24. The characteristic chromosomal imbalances as well as the distinct high-level amplifications previously were not known to be affected in Hodgkin cells.

A very recent CGH analysis on flow-sorted CD30+ Hodgkin cells describes a higher number of imbalances than were found in the present study (14) . However, many of those imbalances seem not to be characteristic because most chromosomal regions were over- and underrepresented at similar frequencies. In addition, the most frequent aberrations affect chromosome regions known to be difficult in CGH analysis (e.g., pericentromeric regions of chromosomes 1 and 9) and therefore are not considered in CGH evaluation (9) .

The unbalanced chromosomal regions detected in the present study include several interesting candidate genes, for example: (a) receptor tyrosine kinase ALK (2p23), which was found to be involved in t(2;5) translocations of ~40% of CD30+ anaplastic large B-cell lymphomas (15) ; (b) the members of the REL/NF-{kappa}B family of transcription factors, REL (2p15) and NF-{kappa}B-p50 (4q23-q24), which have been directly implicated in the pathogenesis of Hodgkin’s lymphoma (16) ; (c) fibroblast growth factor receptor 3 (FGFR3) and multiple myeloma SET domain gene MMSET (4p16), which were found in breakpoint regions of t(4;14)(p16;q32) translocations in multiple myeloma (17) ; and (d) MDM2 (12q14), which is a potent inhibitor of TP53 and is involved in cell cycle control.

It is intriguing that the prominent finding of this study, a gain in chromosome arm 9p in one-third of the cases, is in concordance with previous data of PMBL that revealed a gain of 9p in half of the cases (4 , 12) . This genomic change is rare in other B-cell non-Hodgkin’s lymphomas and was observed only in 7 of >300 cases of B-cell non-Hodgkin’s lymphomas other than PMBL (18) . The high-level amplifications in one Hodgkin case and one PMBL allowed us to narrow the consensus region on 9p to subbands 9p23-p24. Two candidate genes are located within this area. The first, NF1B, encodes for a transcription factor and is involved in chromosomal translocations in pleomorphic adenomas of the salivary gland (19) . The second, JAK2, is involved in the Jak/STAT signal transduction of various cytokines as well as Ras-dependent pathways (20) . We could demonstrate that JAK2 is in fact coamplified in each of the tumors with 9p23-p24 amplification. In addition, the frequent gains of chromosome arms 2p and 12q in Hodgkin cells were found recurrently in ~30% of PMBL tumors as well (4) . On the basis of these similarities, it is tempting to speculate that Hodgkin’s disease and PMBL might share common pathogenetic pathways. In line with this hypothesis is the finding of rare cases of composite lymphomas with features of Hodgkin’s disease and PMBL (21) . In addition, both tumor entities share a number of clinical and immunological features, e.g., their frequent mediastinal origin and the lack of functional expression of HLA class I and immunoglobulin molecules.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by the Tumorzentrum Heidelberg/Mannheim (Grants I./I.1. and I./I.2.) and by the Deutsche Forschungsgemeinschaft (Grants Be 1454/5-2, Li 406/4-1, and SFB 399-A8). Back

2 To whom requests for reprints should be addressed, at Deutsches Krebsforschungszentrum, H0700, D-69120 Heidelberg, Germany. Phone: 49-6221-424620; Fax: 49-6221-424639; E-mail: s.joos{at}dkfz-heidelberg.de Back

3 The abbreviations used are: cHL, classical Hodgkin’s lymphoma; cHL-LR, lymphocyte-rich cHL; cHL-NS, nodular sclerosis cHL; cHL-MC, mixed-cellularity cHL; cHL-LD, lymphocyte-depletion cHL; NLPHL, nodular lymphocyte predominant Hodgkin’s lymphoma; CGH, comparative genomic hybridization; PMBL, primary mediastinal B-cell lymphoma; DOP-PCR, degenerate-oligo-primed-PCR; FISH, fluorescence in situ hybridization. Back

Received 11/ 8/99. Accepted 12/13/99.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K. C., Cleary M. L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K. C., Grogan T. M., Isaacson P. G., Knowles D. M., Mason D. Y., Müller-Hermelink H.-K., Pileri S. A., Piris M. A., Ralfkiaer E., Warnke R. A. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood, 84: 1361-1392, 1994.[Free Full Text]
  2. Warnke R. A., Weiss L. M., Chan J. K. C., Cleary M. L., Dorfman R. F. Tumors of the lymph nodes and spleen Rosai J. Sobin L. H. eds. . Atlas of Tumor Pathology, 14: 43-62, Armed Forces Institute of Pathology Washington, DC 1995.
  3. Atkin N. B. Cytogenetics of Hodgkin’s disease. Cytogenet. Cell Genet., 80: 23-27, 1998.[Medline]
  4. Joos S., Otaño-Joos M. I., Ziegler S., Brüderlein S., du Manoir S., Bentz M., Möller P., Lichter P. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood, 87: 1571-1578, 1996.[Abstract/Free Full Text]
  5. Jaffe E., Harris N., Diebold J., Müller-Hermelink H.-K. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Am. J. Clin. Pathol., 111(Suppl.1): 8-12, 1999.
  6. Roth J., Daus H., Trümper L., Gause A., Salamon-Looijen M., Pfreundschuh M. G. Detection of immunoglobulin heavy-chain gene rearrangement at the single-cell level in malignant lymphomas: no rearrangement is found in Hodgkin and Reed-Sternberg cells. Int. J. Cancer, 57: 799-804, 1994.[Medline]
  7. Telenius H., Pelmear A., Tunnacliffe A., Carter N., Behmel A., Ferguson-Smith M., Nordenskjöld M., Pfragner R., Ponder B. Cytogenetic analysis by chromosome painting using DOP-PCR amplified flow-sorted chromosomes. Genes Chromosomes Cancer, 4: 257-263, 1992.[Medline]
  8. Lichter P., Bentz M., du Manoir S., Joos S. Comparative genomic hybridization Verma R. S. Babu A. eds. . Human Chromosomes, : 191-210, McGraw Hill New York 1995.
  9. Kallioniemi O.-P., Kallioniemi A., Piper J., Isola J., Waldman F. M., Gray J. W., Pinkel D. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer, 10: 231-243, 1994.[Medline]
  10. Cools J., Peeters P., Voet T., Aventin A., Mecucci C., Grandchamp B., Marynen P. Genomic organization of human JAK2 and mutation analysis of its JH2-domain in leukemia. Cytogenet. Cell Genet., 85: 260-266, 1999.[Medline]
  11. Maniatis, T., Fritsch, E. F., and Sambrook, J. Molecular Cloning: A Laboratory Manual. New York, NY: Cold Spring Harbor Laboratory, 1982.
  12. Scarpa A., Taruscio D., Scardoni M., Iosi F., Paradisi S., Ennas M. G., Rigaud G., Moore P. S., Menestrina F. Nonrandom chromosomal imbalances in primary mediastinal B-cell lymphoma detected by arbitrarily primed PCR fingerprinting. Genes Chromosomes Cancer, 26: 203-209, 1999.[Medline]
  13. Weber R. G., Scheer M., Born A., Joos S., Cobbers J. M. J. L., Hofele C., Reifenberger G., Zöller J. E., Lichter P. Recurrent chromosomal imbalances detected in biopsy material from oral premalignant and malignant lesions by combined tissue microdissection, universal DNA amplification, and comparative genomic hybridization. Am. J. Pathol., 153: 295-303, 1998.[Abstract/Free Full Text]
  14. Ohshima K., Ishiguro M., Ohgami A., Sugihara M., Haraoka S., Suzumiya J., Kikuchi M. Genetic analysis of sorted Hodgkin and Reed-Sternberg cells using comparative genomic hybridization. Int. J. Cancer, 82: 250-255, 1999.[Medline]
  15. Herbst H., Anagnostopoulos J., Heinze B., Durkop H., Hummel M., Stein H. ALK gene products in anaplastic large cell lymphomas and Hodgkin’s disease. Blood, 86: 1694-1700, 1995.[Abstract/Free Full Text]
  16. Bargou R., Emmerich F., Krappmann D., Bommert K., Mapara M., Arnold W., Royer H., Grinstein E., Greiner A., Scheidereit C., Dorken B. Constitutive nuclear factor-{kappa}B-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J. Clin. Investig., 100: 2961-2969, 1997.[Medline]
  17. Chesi M., Nardini E., Lim R., Smith K., Kuehl W., Bergsagel P. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood, 92: 3025-3034, 1998.[Abstract/Free Full Text]
  18. Bentz M., Barth T. F. E., Feller A. C., Bock D., Schlotter M., Lichter P., Döhner P., Möller P. Gains of chromosome arm 9p are frequent in primary mediastinal B-cell neoplasms. Blood, 92(Suppl.1): 240a 1998.
  19. Geurts J., Schoenmakers E., Roijer E., Astrom A., Stenman G., van de Ven W. Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene, 19: 865-872, 1998.
  20. Ihle J. N., Kerr I. A. Jaks, and STATs in signaling by the cytokine receptor superfamily. Trends Genet., 11: 69-74, 1995.[Medline]
  21. Rüdiger T., Jaffe E., Delsol G., deWolf-Peeters C., Gascoyne R., Georgii A., Harris N., Kadin M., MacLennan K., Poppema S., Stein H., Weiss L., Muller-Hermelink H. Workshop report on Hodgkin’s disease and related diseases (‘grey zone’ lymphoma). Ann. Oncol., 9(Suppl.5): 31-38, 1998.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 haematolHome page
T. Feys, B. Poppe, K. De Preter, N. Van Roy, B. Verhasselt, P. De Paepe, A. De Paepe, and F. Speleman
A detailed inventory of DNA copy number alterations in four commonly used Hodgkin's lymphoma cell lines
Haematologica, July 1, 2007; 92(7): 913 - 920.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. I. Martin-Subero, W. Klapper, A. Sotnikova, E. Callet-Bauchu, L. Harder, C. Bastard, R. Schmitz, S. Grohmann, J. Hoppner, J. Riemke, et al.
Chromosomal Breakpoints Affecting Immunoglobulin Loci Are Recurrent in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Cancer Res., November 1, 2006; 66(21): 10332 - 10338.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Kasugai, H. Tagawa, Y. Kameoka, Y. Morishima, S. Nakamura, and M. Seto
Identification of CCND3 and BYSL as Candidate Targets for the 6p21 Amplification in Diffuse Large B-Cell Lymphoma
Clin. Cancer Res., December 1, 2005; 11(23): 8265 - 8272.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. L. Levine, M. Loriaux, B. J. P. Huntly, M. L. Loh, M. Beran, E. Stoffregen, R. Berger, J. J. Clark, S. G. Willis, K. T. Nguyen, et al.
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
Blood, November 15, 2005; 106(10): 3377 - 3379.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Re, R. Kuppers, and V. Diehl
Molecular Pathogenesis of Hodgkin's Lymphoma
J. Clin. Oncol., September 10, 2005; 23(26): 6379 - 6386.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Re, R. K. Thomas, K. Behringer, and V. Diehl
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
Blood, June 15, 2005; 105(12): 4553 - 4560.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Melzner, A. J. Bucur, S. Bruderlein, K. Dorsch, C. Hasel, T. F. E. Barth, F. Leithauser, and P. Moller
Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line
Blood, March 15, 2005; 105(6): 2535 - 2542.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. J. Savage, S. Monti, J. L. Kutok, G. Cattoretti, D. Neuberg, L. de Leval, P. Kurtin, P. D. Cin, C. Ladd, F. Feuerhake, et al.
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
Blood, December 1, 2003; 102(12): 3871 - 3879.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
A. Rosenwald, G. Wright, K. Leroy, X. Yu, P. Gaulard, R. D. Gascoyne, W. C. Chan, T. Zhao, C. Haioun, T. C. Greiner, et al.
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
J. Exp. Med., September 15, 2003; 198(6): 851 - 862.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Re, P. Starostik, N. Massoudi, A. Staratschek-Jox, V. Dries, R. K. Thomas, V. Diehl, and J. Wolf
Allelic Losses on Chromosome 6q25 in Hodgkin and Reed Sternberg Cells
Cancer Res., May 15, 2003; 63(10): 2606 - 2609.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. F. E. Barth, J. I. Martin-Subero, S. Joos, C. K. Menz, C. Hasel, G. Mechtersheimer, R. M. Parwaresch, P. Lichter, R. Siebert, and P. Moller
Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma
Blood, May 1, 2003; 101(9): 3681 - 3686.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Copie-Bergman, M.-L. Boulland, C. Dehoulle, P. Moller, J.-P. Farcet, M. J. S. Dyer, C. Haioun, P.-H. Romeo, P. Gaulard, and K. Leroy
Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma
Blood, April 1, 2003; 101(7): 2756 - 2761.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
E. M. Maggio, A. van den Berg, D. de Jong, A. Diepstra, and S. Poppema
Low Frequency of FAS Mutations in Reed-Sternberg Cells of Hodgkin's Lymphoma
Am. J. Pathol., January 1, 2003; 162(1): 29 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Franke, I. Wlodarska, B. Maes, P. Vandenberghe, R. Achten, A. Hagemeijer, and C. De Wolf-Peeters
Comparative Genomic Hybridization Pattern Distinguishes T-Cell/Histiocyte-Rich B-Cell Lymphoma from Nodular Lymphocyte Predominance Hodgkin's Lymphoma
Am. J. Pathol., November 1, 2002; 161(5): 1861 - 1867.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Joos, C. K. Menz, G. Wrobel, R. Siebert, S. Gesk, S. Ohl, G. Mechtersheimer, L. Trumper, P. Moller, P. Lichter, et al.
Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2
Blood, February 15, 2002; 99(4): 1381 - 1387.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. I. Martin-Subero, S. Gesk, L. Harder, T. Sonoki, P. W. Tucker, B. Schlegelberger, W. Grote, F. J. Novo, M. J. Calasanz, M. L. Hansmann, et al.
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma
Blood, February 15, 2002; 99(4): 1474 - 1477.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Satterwhite, T. Sonoki, T. G. Willis, L. Harder, R. Nowak, E. L. Arriola, H. Liu, H. P. Price, S. Gesk, D. Steinemann, et al.
The BCL11 gene family: involvement of BCL11A in lymphoid malignancies
Blood, December 1, 2001; 98(12): 3413 - 3420.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Leithauser, M. Bauerle, M. Q. Huynh, and P. Moller
Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma
Blood, November 1, 2001; 98(9): 2762 - 2770.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Kube, U. Holtick, M. Vockerodt, T. Ahmadi, B. Haier, I. Behrmann, P. C. Heinrich, V. Diehl, and H. Tesch
STAT3 is constitutively activated in Hodgkin cell lines
Blood, August 1, 2001; 98(3): 762 - 770.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Franke, I. Wlodarska, B. Maes, P. Vandenberghe, J. Delabie, A. Hagemeijer, and C. De Wolf-Peeters
Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances
Blood, March 15, 2001; 97(6): 1845 - 1853.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Joos, S.
Right arrow Articles by Lichter, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joos, S.
Right arrow Articles by Lichter, P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online